With the results of several studies in the field of molecular genetics in IP, the genetic biomarkers appear to be strongly associated with an increased risk of developing IP; others, such as IL-1α, IL-1β, TNF-α, MMP8, OPG, and inflammatory cytokines, demonstrate some variability or inconsistent results in modulating immune responses and consequently influencing peri-implant bone loss. This evidence concerns the gene IL1A and incontinentia pigmenti.